Retatrutide product description — Triple hormone receptor agonist peptide
Retatrutide
An investigational once-weekly triple hormone receptor agonist activating GLP-1, GIP, and Glucagon receptors simultaneously. The highest weight reduction reported in the incretin class. Purity >99% · Double lab tested.
Regulatory status
Mechanism of action — triple receptor
Insulin & appetite control
Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite centrally — the same broad effects as semaglutide.
Augmented glucose control
Amplifies glucose-dependent insulin release; also influences adipose tissue and central pathways relevant to body weight regulation.
Energy expenditure & lipolysis
Raises basal energy expenditure and promotes lipolysis — the key differentiator from dual agonists like tirzepatide, driving superior weight loss.
Clinical trial evidence
12 mg weekly · 48 weeks
Significant pain reduction
Significant weight loss
Adverse effects & safety
Adverse-effect profile is broadly consistent with the GLP-1 class — gastrointestinal symptoms predominate, particularly during dose escalation: nausea, vomiting, diarrhea, and constipation.




Reviews
There are no reviews yet.